February 4th, 2010 by Jonathan Foulds, Ph.D. in Better Health Network, News, Research
No Comments »
Most smokers dread lung cancer. They are aware that by continuing to smoke the chances of developing lung cancer are increased 20 times, and that once it has developed the treatment is unpleasant and prognosis poor. Many patients (and unfortunately many clinicians) assume that once you have lung cancer it is too late to quit.
This week a new report was published in the BMJ, based on a review of the evidence that smoking cessation after diagnosis of a primary lung tumour affects prognosis. The study, by Drs Parsons, Daley and Aveyard at the UK Centre for Tobacco Control Studies, combined the data from 10 studies. They found that those who quit smoking after diagnosis were significantly less likely to develop another tumor and significantly more likely to still be alive 5 years later. Read more »
This post, Once You Have Lung Cancer, Should You Bother To Quit Smoking?, was originally published on
Healthine.com by Jonathan Foulds, Ph.D..
January 29th, 2010 by Dr. Val Jones in Humor, Research
No Comments »
Thanks to Harriet Hall, I found this hilarious spoof article from the BMJ which perfectly illustrates why “Evidence-Based Medicine” (EBM) alone is not sufficient for answering medical questions. The abstract perfectly illustrates why randomized controlled trials must be viewed within the context of general scientific knowledge rather than in isolation. The weakness of EBM has been an over-reliance on “methodolatry” – resulting in conclusions made without consideration of prior probability, laws of physics, or plain common sense.
EBM is valuable but not sufficient for drawing accurate conclusions… which is why Steve Novella and the Science Based Medicine team have proposed that our quest for reliable information (upon which to make informed health decisions) should be based on good science rather than EBM alone.
Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials
Gordon C S Smith, professor1, Jill P Pell, consultant2
Read more »
